抗 BCMA/GPRC5D CAR-T 细胞用于伴骨外髓外病变的复发/难治性多发性骨髓瘤患者

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸

Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.

超越双靶向：重新定义真正髓外骨髓瘤的治疗格局？——一项批判性评价

Beyond dual targeting: redefining the treatment horizon for true extramedullary myeloma? - a critical appraisal.

病例报告：抗 BCMA/GPRC5D 双特异性 CAR-T 细胞治疗多发性骨髓瘤中多次 CAR-T 扩增的总结

Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma.

更正：BCMA/GPRC5D 双特异性 CAR-T 细胞治疗伴髓外病变的复发/难治性多发性骨髓瘤：一项单中心、单臂、1 期试验

Correction: BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-ar

BCMA/GPRC5D 双特异性 CAR-T 细胞治疗伴髓外病变的复发/难治性多发性骨髓瘤：单中心、单臂、I 期试验

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 t

揭示多发性骨髓瘤中因果免疫细胞-基因关联：系统综述与孟德尔随机化分析的启示

Unveiling causal immune cell-gene associations in multiple myeloma: insights from systematic reviews and Mendelian randomization analyses.

我们的研究支持 CAR-T 细胞疗法在 rrMM 患者中的疗效和安全性，ORR 为 82.2%，严重 CRS（6.3%）和神经毒性（0.9%）发生率低。这一发现还提示 BCMA/CD19 双特异性 CAR-T 细胞具有更优的 ORR，尚待临床确认。MR 分析揭示了免疫细胞、VDR 和 VHL 等基因与 MM 之间的关联，增进了我们对其病理生理学的理解。

抗 BCMA/GPRC5D 双特异性 CAR-T 细胞治疗复发/难治性多发性骨髓瘤患者：一项单臂、单中心、1 期试验

Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.

抗 BCMA/GPRC5D 双特异性 CAR-T 细胞在复发/难治性多发性骨髓瘤患者中显示出良好的安全性特征和令人鼓舞的活性。

靶向 BCMA/GPRC5D 的双特异性 CAR-T 细胞治疗复发/难治性多发性骨髓瘤：1 + 1 是否大于 2？

Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?